Personalized Nanomedicine
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Preparing Pathology for Personalized Medicine: Possibilities for Improvement of the Pre-Analytical Phase
Preparing pathology for personalized medicine: possibilities for improvement of the pre-analytical phase. Patricia Jta Groenen, Willeke A Blokx, Coos Diepenbroek, Lambert Burgers, Franco Visinoni, Pieter Wesseling, Han van Krieken To cite this version: Patricia Jta Groenen, Willeke A Blokx, Coos Diepenbroek, Lambert Burgers, Franco Visinoni, et al.. Preparing pathology for personalized medicine: possibilities for improvement of the pre-analytical phase.. Histopathology, Wiley, 2011, 59 (1), pp.1. 10.1111/j.1365-2559.2010.03711.x. hal-00630795 HAL Id: hal-00630795 https://hal.archives-ouvertes.fr/hal-00630795 Submitted on 11 Oct 2011 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Histopathology Preparing pathology for personalized medicine: possibilities for improvement of the pre-analytical phase. For Peer Review Journal: Histopathology Manuscript ID: HISTOP-08-10-0429 Wiley - Manuscript type: Review Date Submitted by the 06-Aug-2010 Author: Complete List of Authors: Groenen, Patricia; Radboud University Nijmegen Medical Centre, Pathology Blokx, -
COVID-19 Publications - Week 05 2021 1328 Publications
Update February 1 - February 7, 2021, Dr. Peter J. Lansberg MD, PhD Weekly COVID-19 Literature Update will keep you up-to-date with all recent PubMed publications categorized by relevant topics COVID-19 publications - Week 05 2021 1328 Publications PubMed based Covid-19 weekly literature update For those interested in receiving weekly updates click here For questions and requests for topics to add send an e-mail [email protected] Reliable on-line resources for Covid 19 WHO Cochrane Daily dashbord BMJ Country Guidance The Lancet Travel restriction New England Journal of Medicine Covid Counter JAMA Covid forcasts Cell CDC Science AHA Oxford Universtiy Press ESC Cambridge Univeristy Press EMEA Springer Nature Evidence EPPI Elsevier Wikipedia Wiley Cardionerds - COVID-19 PLOS Genomic epidemiology LitCovid NIH-NLM Oxygenation Ventilation toolkit SSRN (Pre-prints) German (ICU) bed capacity COVID reference (Steinhauser Verlag) COVID-19 Projections tracker Retracted papers AAN - Neurology resources COVID-19 risk tools - Apps COVID-19 resources (Harvard) Web app for SARS-CoV2 mutations COVID-19 resources (McMasters) COVID-19 resources (NHLBI) COVID-19 resources (MEDSCAPE) COVID-19 Diabetes (JDRF) COVID-19 TELEMEDICINE (BMJ) Global Causes of death (Johns Hopkins) COVID-19 calculators (Medscap) Guidelines NICE Guidelines Covid-19 Korean CDC Covid-19 guidelines Flattening the curve - Korea IDSA COVID-19 Guidelines Airway Management Clinical Practice Guidelines (SIAARTI/EAMS, 2020) ESICM Ventilation Guidelines Performing Procedures on Patients With -
Personalized Medicine: Definitions, History, and Implications for the OT Profession
The Open Journal of Occupational Therapy Volume 3 Issue 4 Fall 2015 Article 1 October 2015 Personalized medicine: Definitions, history, and implications for the OT profession Diane Powers Dirette Western Michigan University - USA, [email protected] Follow this and additional works at: https://scholarworks.wmich.edu/ojot Part of the Occupational Therapy Commons Recommended Citation Dirette, D. P. (2015) "Personalized medicine: Definitions, history, and implications for the OT profession," The Open Journal of Occupational Therapy: Vol. 3: Iss. 4, Article 1. Available at: https://doi.org/10.15453/ 2168-6408.1213 This document has been accepted for inclusion in The Open Journal of Occupational Therapy by the editors. Free, open access is provided by ScholarWorks at WMU. For more information, please contact wmu- [email protected]. Personalized medicine: Definitions, history, and implications for the OT profession Keywords individualized medicine, personalized medicine, precision medicine, stratified medicine, paradigm shifts Credentials Display Diane Powers Dirette, Ph.D., OTL Copyright transfer agreements are not obtained by The Open Journal of Occupational Therapy (OJOT). Reprint permission for this Letter from the Editor should be obtained from the corresponding author(s). Click here to view our open access statement regarding user rights and distribution of this Letter from the Editor. DOI: 10.15453/2168-6408.1213 This letter from the editor is available in The Open Journal of Occupational Therapy: https://scholarworks.wmich.edu/ ojot/vol3/iss4/1 Dirette: Personalized medicine in OT That dreaded phone call comes from your treatment of leukemia, cystic fibrosis, liver cancer physician in the middle of the day informing you of (Kaiser, 2015), lung cancer (Eisenstein, 2014), the results of your biopsy that was ordered amyotrophic lateral sclerosis (Cashman & Ospri, following an abnormal mammogram. -
Personalized Medicine: the Impact of Molecular Testing on Patient Care
Personalized Medicine: The Impact of Molecular Testing on Patient Care Mini-Elective Spring 2020 University Course Dates: January 17, 24, 31, February 7, 14 Fridays, 2:30-4:30 PM of Pittsburgh Maximum Students: 5 School of Class Year: MS1 and MS2 Medicine Course Directors: Simion Chiosea, MD Professor of Pathology Somak Roy, MD Assistant Professor of Pathology Contact Information: Lynn Wolkenstein 412-647-7065 [email protected] Jessica Tebbets 412-802-6797 [email protected] Registration: Betsy Nero, Office of Medical Education [email protected] Description: Personalized medicine applies knowledge of molecular data for early disease detection, targeted treatment, and detection of person’s predisposition to a particular disease. It improves diagnosis and treatment of a disease and advances effectiveness of healthcare. This mini-elective is based in the Department of Pathology and will introduce students to principles and current applications of personalized medicine. During mini-elective students will be able to observe and discuss the principles of molecular testing, become familiar with the clinical interpretation of molecular results in all areas of medicine, including oncology, neuro-oncology, endocrinology, and gastroenterology. The training will be conducted in the clinical Molecular and Genomic Pathology (MGP) laboratory, Department of Pathology, University of Pittsburgh. MGP laboratory is one of the largest laboratories in the US focused on molecular diagnostics of solid tumors. It processes over 22,000 samples each year using high-throughput technologies, such as Next Generation Sequencing (NGS) and a variety of the conventional molecular biology techniques. It performs molecular testing for all hospitals of the UPMC system and serves as reference laboratory for other medical centers across the United States. -
Assessment of Pharmacist's Knowledge and Perception Toward
pharmacy Article Assessment of Pharmacist’s Knowledge and Perception toward 3D Printing Technology as a Dispensing Method for Personalized Medicine and the Readiness for Implementation Mohammed S. Algahtani Department of Pharmaceutics, College of Pharmacy, Najran University, Najran 1988, Saudi Arabia; [email protected]; Tel.: +966-17-458-7200 Abstract: The main user of three dimensional (3D) printing for drug dispensing will be the hospital pharmacist. Yet despite the tremendous amount of research and industrial initiatives, there is no evaluation of the pharmacist’s knowledge and opinion of this technology. The present study aimed to assess knowledge and attitude among pharmacists about 3D printing technology as an innovative dispensing method for personalized medicine and the barriers to implementation in Saudi Arabia. We found that 53% of participants were aware of 3D printing technology in general, but only 14–16% of pharmacists were aware of the specific application of 3D printing in drug dispensing. Participants showed a positive perception regarding the concept of personalized medicine and that 3D printing could provide a promising solution to formulate and dispense personalized medicine in the pharmacy. It was also found that 67% of pharmacists were encouraged to adopt this new technology for drug dispensing, reflecting their willingness to learn new innovations. However, the technology cost, regulation, and the shortage of practicing pharmacists were also reported as the top barriers for Citation: Algahtani, M.S. Assessment of Pharmacist’s implementation. Facilitating the implementation of this technology in the pharmacy practice will Knowledge and Perception toward require a strategic plan in which pharmacists collaborate with regulatory bodies and 3D printing 3D Printing Technology as a engineers to overcome challenges and barriers to implement such promising technology. -
Design and Characterization of Inulin Conjugate for Improved Intracellular and Targeted Delivery of Pyrazinoic Acid to Monocytes
pharmaceutics Article Design and Characterization of Inulin Conjugate for Improved Intracellular and Targeted Delivery of Pyrazinoic Acid to Monocytes Franklin Afinjuomo 1, Thomas G. Barclay 1, Ankit Parikh 1, Yunmei Song 1, Rosa Chung 1, Lixin Wang 1, Liang Liu 1, John D. Hayball 1, Nikolai Petrovsky 2,3 and Sanjay Garg 1,* 1 School of Pharmacy and Medical Sciences, University of South Australia, Adelaide, SA 5001, Australia; olumide.afi[email protected] (F.A.); [email protected] (T.G.B.); [email protected] (A.P.); [email protected] (Y.S.); [email protected] (R.C.); [email protected] (L.W.); [email protected] (L.L.); [email protected] (J.D.H.) 2 Vaxine Pty. Ltd., Adelaide, SA 5042, Australia; nikolai.petrovsky@flinders.edu.au 3 Department of Endocrinology, Flinders University, Adelaide, SA 5042, Australia * Correspondence: [email protected]; Tel.: +61-8-8302-1567 Received: 26 April 2019; Accepted: 16 May 2019; Published: 22 May 2019 Abstract: The propensity of monocytes to migrate into sites of mycobacterium tuberculosis (TB) infection and then become infected themselves makes them potential targets for delivery of drugs intracellularly to the tubercle bacilli reservoir. Conventional TB drugs are less effective because of poor intracellular delivery to this bacterial sanctuary. This study highlights the potential of using semicrystalline delta inulin particles that are readily internalised by monocytes for a monocyte-based drug delivery system. Pyrazinoic acid was successfully attached covalently to the delta inulin particles via a labile linker. -
Advances in Nanomaterials in Biomedicine
nanomaterials Editorial Advances in Nanomaterials in Biomedicine Elena Ryabchikova Institute of Chemical Biology and Fundamental Medicine, Siberian Branch of Russian Academy of Science, 8 Lavrentiev Ave., 630090 Novosibirsk, Russia; [email protected] Keywords: nanotechnology; nanomedicine; biocompatible nanomaterials; diagnostics; nanocarriers; targeted drug delivery; tissue engineering Biomedicine is actively developing a methodological network that brings together biological research and its medical applications. Biomedicine, in fact, is at the front flank of the creation of the latest technologies for various fields in medicine, and, obviously, nanotechnologies occupy an important place at this flank. Based on the well-known breadth of the concept of “Biomedicine”, the boundaries of the Special Issue “Advances in Nanomaterials in Biomedicine” were not limited, and authors could present their work from various fields of nanotechnology, as well as new methods and nanomaterials intended for medical applications. This approach made it possible to make public not only specific developments, but also served as a kind of mirror reflecting the most active interest of researchers in a particular field of application of nanotechnology in biomedicine. The Special Issue brought together more than 110 authors from different countries, who submitted 11 original research articles and 7 reviews, and conveyed their vision of the problems of nanomaterials in biomedicine to the readers. A detailed and well-illustrated review on the main problems of nanomedicine in onco-immunotherapy was presented by Acebes-Fernández and co-authors [1]. It should be noted that the review is not limited to onco-immunotherapy, and gives a complete understanding of nanomedicine in general, which is useful for those new to this field. -
Paving the Way for Personalized Medicine
OCTOBER 2013 Paving the Way for Personalized Medicine FDA’s Role in a New Era of Medical Product Development U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES U.S. FOOD AND DRUG ADMINISTRATION Paving the Way for Personalized Medicine: FDA’s Role in a New Era of Medical Product Development COMMISSIONER’S MESSAGE 2 I. INTRODUCTION 3 II. PERSONALIZED MEDICINE FROM A REGULATORY PERSPECTIVE 5 1. DEFINING PERSONALIZED MEDICINE 5 2. FDA’S UNIQUE ROLE AND RESPONSIBILITIES IN PERSONALIZED MEDICINE 11 III. DRIVING TOWARD AND RESPONDING TO SCIENTIFIC ADVANCES 14 1. BUILDING THE INFRASTRUCTURE TO SUPPORT PERSONALIZED MEDICINE 16 2. RECENT ORGANIZATIONAL EFFORTS 20 IV. DEFINING AND CLARIFYING REGULATORY PATHWAYS AND POLICIES 23 1. ENSURING THE AVAILABILITY OF SAFE AND EFFECTIVE DIAGNOSTICS 29 2. PRODUCT INTERDEPENDENCY 32 3. PRODUCT LABELING 36 4. POST-MARKET SURVEILLANCE 40 V. ADVANCING REGULATORY SCIENCE IN SUPPORT OF PERSONALIZED MEDICINE 42 1. DEVELOPING REGULATORY STANDARDS, RESEARCH METHODS, AND TOOLS 42 2. CONDUCTING AND COLLABORATING IN RESEARCH 47 VI. A NEW ERA OF MEDICAL PRODUCT DEVELOPMENT: OPPORTUNITIES AND CHALLENGES AHEAD 54 GLOSSARY OF TERMS 58 ENDNOTES 60 ver the past few years, a number of products that signal a new era of medical product development have entered the market or come on the horizon. In just the last two years, the FDA approved four cancer drugs for use in patients whose tumors have specific genetic characteristics that Oare identified by a companion diagnostic test. Last year, FDA approved a new therapy for use in certain cystic fibrosis patients with a specific genetic mutation. Earlier this year, three-dimensional (3D) printing was used to create a bioresorbable tracheal splint for treating a critically-ill infant. -
Introduction to Genomic Medicine
Introduction to Genomic Medicine What is genomic medicine? There are more than 7 billion people on our planet, each a massive collection of about 100 trillion cells. How do these cells know what to do? What tells them to work together to keep your brain thinking, heart pumping, and hair growing? The answer lies in a long, winding molecule called deoxyribonucleic acid, or DNA. DNA could be referred to as an instruction manual on how cells work as it contains genes that carry instructions needed to build and maintain the many different types of cells that make us unique. Researchers call this complete set of DNA instructions a “genome.” Our health is determined by our inherited or acquired genetic differences combined with our lifestyles and other environmental factors. Although greater than 99.9% of a DNA sequence is identical from person to person, the last 0.1% helps to explain these differences. Different people may have small variations in specific genes, and some people may have genes that others do not. These may increase susceptibility to a specific disease or provide protection from that illness. By combining and analysing information about our genome, with clinical and diagnostic information and then comparing that with data from others, patterns can be identified. Together this information can help to determine our individual risk of developing disease, detect illness earlier, provide accurate diagnosis, support disease monitoring and determine the most effective interventions to help improve our health, either by the use of medication or lifestyle choices. Genomic medicine describes these efforts. Genomic medicine sometimes also known as personalized medicine is a move away from a ‘one size fits all’ approach to the treatment and care of patients with a particular condition, to one which uses new approaches to better manage patients’ health and target therapies to achieve the best outcomes in the management of a patient’s disease or predisposition to disease. -
Definition of Personalized Medicine and Targeted Therapies
Journal of Personalized Medicine Article Definition of Personalized Medicine and Targeted Therapies: Does Medical Familiarity Matter? Valentyn Fournier 1,* , Thomas Prebet 2, Alexandra Dormal 2, Maïté Brunel 1, Robin Cremer 3 and Loris Schiaratura 1 1 University of Lille, ULR 4072—PSITEC—Psychologie: Interactions, Temps, Emotions, Cognition, F-59000 Lille, France; [email protected] (M.B.); [email protected] (L.S.) 2 Yale Cancer Center, Yale University, 333 Cedar Street, New Haven, CT 06520, USA; [email protected] (T.P.); [email protected] (A.D.) 3 Espace éthique régional des Hauts-de-France, Centre Hospitalier Universitaire de Lille, F-59037 Lille, France; [email protected] * Correspondence: [email protected] Abstract: Personalized medicine (PM) is increasingly becoming a topic of discussion in public health policies and media. However, there is no consensus among definitions of PM in the scientific literature and the terms used to designate it, with some definitions emphasizing patient-centered aspects and others emphasizing biomedical aspects. Furthermore, terms used to refer to PM (e.g., “pharmacogenomics” or, more often, “targeted therapies”) are diverse and differently used. To our knowledge, no study has apprehended the differences of definition and attitudes toward personalized medicine and targeted therapies according to level of familiarity with the medical field. Our cohort included 349 French students from three different academic fields, which modulated their familiarity level with the medical field. They were asked to associate words either to “personalized medicine” or “target therapies”. Then, they were asked to give an emotional valence to their associations. -
Introducing Bionanotechnology Into Undergraduate Biomedical Engineering
AC 2009-504: INTRODUCING BIONANOTECHNOLOGY INTO UNDERGRADUATE BIOMEDICAL ENGINEERING Aura Gimm, Duke University J. Aura Gimm is Assistant Professor of the Practice and Associated Director of Undergraduate Studies in the Department of Biomedical Engineering at Duke University. She teaches courses in biomaterials, thermodynamics/kinetics, engineering design, and a new course in bionanotechnology. Dr. Gimm received her S.B. in Chemical Engineering and Biology from MIT, and her Ph.D. in Bioengineering from UC-Berkeley. Page 14.802.1 Page © American Society for Engineering Education, 2009 Introducing Bionanotechnology in Undergraduate Biomedical Engineering Abstract As a part of the NSF-funded Nanotechnology Undergraduate Education Program, we have developed and implemented a new upper division elective course in Biomedical Engineering titled “Introduction to Bionanotechnology Engineering”. The pilot course included five hands- on “Nanolab” modules that guided students through specific aspects of nanomaterials and engineering design in addition to lecture topics such as scaling effects, quantum effects, electrical/optical properties at nanoscale, self-assembly, nanostructures, nanofabrication, biomotors, biological designing, biosensors, etc. Students also interacted with researchers currently working in the areas of nanomedicine, self-assembly, tribiology, and nanobiomaterials to learn first-hand the engineering and design challenges. The course culminated with research or design proposals and oral presentations that addressed specific engineering/design issues facing nanobiotechnology and/or nanomedicine. The assessment also included an exam (only first offering), laboratory write-ups, reading of research journal articles and analysis, and an essay on ethical/societal implications of nanotechnology, and summative questionnaire. The course exposed students to cross-disciplinary intersections that occur between biomedical engineering, materials science, chemistry, physics, and biology when working at the nanoscale. -
Nanotechnology in Regenerative Medicine: the Materials Side
View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by UPCommons. Portal del coneixement obert de la UPC Review Nanotechnology in regenerative medicine: the materials side Elisabeth Engel, Alexandra Michiardi, Melba Navarro, Damien Lacroix and Josep A. Planell Institute for Bioengineering of Catalonia (IBEC), Department of Materials Science, Technical University of Catalonia, CIBER BBN, Barcelona, Spain Regenerative medicine is an emerging multidisciplinary structures and materials with nanoscale features that can field that aims to restore, maintain or enhance tissues mimic the natural environment of cells, to promote certain and hence organ functions. Regeneration of tissues can functions, such as cell adhesion, cell mobility and cell be achieved by the combination of living cells, which will differentiation. provide biological functionality, and materials, which act Nanomaterials used in biomedical applications include as scaffolds to support cell proliferation. Mammalian nanoparticles for molecules delivery (drugs, growth fac- cells behave in vivo in response to the biological signals tors, DNA), nanofibres for tissue scaffolds, surface modifi- they receive from the surrounding environment, which is cations of implantable materials or nanodevices, such as structured by nanometre-scaled components. Therefore, biosensors. The combination of these elements within materials used in repairing the human body have to tissue engineering (TE) is an excellent example of the reproduce the correct signals that guide the cells great potential of nanotechnology applied to regenerative towards a desirable behaviour. Nanotechnology is not medicine. The ideal goal of regenerative medicine is the in only an excellent tool to produce material structures that vivo regeneration or, alternatively, the in vitro generation mimic the biological ones but also holds the promise of of a complex functional organ consisting of a scaffold made providing efficient delivery systems.